I visited the SENS lab in Mountain View in April of last year and was disappointed when no one I spoke to (Aubrey was absent, being his birthday of all coincidences) had heard of Givewell. So glad to see potential progress on them being considered.
But Holden’s overview of the biomedical charity landscape is also concerning; perhaps one with the goal of defeating aging should in fact be focusing funds on closing the Valley of Death and/or reforming the drug approval process?
I visited the SENS lab in Mountain View in April of last year and was disappointed when no one I spoke to (Aubrey was absent, being his birthday of all coincidences) had heard of Givewell. So glad to see potential progress on them being considered.
But Holden’s overview of the biomedical charity landscape is also concerning; perhaps one with the goal of defeating aging should in fact be focusing funds on closing the Valley of Death and/or reforming the drug approval process?